Therapeutics News and Research

RSS

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

TAVI procedure effective in patients unsuitable for surgical valve replacement: Study

One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

23 Sep 2010

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

23 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010

CSI to present CALCIUM 360° Study results at TCT symposium

Cardiovascular Systems, Inc., announced today that its CALCIUM 360° Study, the first-of-its kind prospective, randomized feasibility study, demonstrated the safety and effectiveness of plaque modification with the Diamondback 360 PAD System versus the standard of care treatment (balloon angioplasty) in below-the-knee arteries.

23 Sep 2010

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.

23 Sep 2010

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

23 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

Anthera Pharmaceuticals closes financing transaction

Anthera Pharmaceuticals, Inc., today announced that it has entered into definitive agreements with certain accredited investors in connection with a private placement, or PIPE, financing transaction pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

23 Sep 2010

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberte Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.

23 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.

22 Sep 2010

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique was safe and feasible. The results of the study were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.

22 Sep 2010

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific Corporation today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.

22 Sep 2010

Study: New percutaneous mitral valve clip offers marked clinical benefit

A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation, according to a study presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

Therapeutics News and Research

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

St. Jude Medical to highlight OCT product platform at TCT meeting

TAVI procedure effective in patients unsuitable for surgical valve replacement: Study

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

CSI to present CALCIUM 360° Study results at TCT symposium

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Anthera Pharmaceuticals closes financing transaction

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

AACR to host fourth International Conference on Molecular Diagnostics

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Study: New percutaneous mitral valve clip offers marked clinical benefit

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News